New hope for young brain cancer patients: enzyme therapy targets tumors
NCT ID NCT07389278
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this combination is safe and helps keep the cancer from progressing for longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADI-PEG 20 (a modified enzyme that breaks down arginine, a nutrient some cancers need to grow)
What this could lead to
If it works, this could point toward a more effective treatment for children and young adults with high-grade glioma, potentially slowing tumor growth.
What could go wrong
This is an early phase 1/2 trial with only 97 participants, so results may not apply to everyone. The added drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact